Research Interests
Platinum-based chemotherapy
Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2
Platinum-based chemotherapy, with cytoreductive surgery, is the cornerstone of treatment of advanced ovarian cancer, however acquired drug resistance is a major clinical obstacle. It has been proposed that subpopulations of tumour cells with stem-cell like properties, such as so-called side populations (SP) which over-express ABC drug-transporters, can sustain the growth of drug resistant tumour cells, leading to tumour recurrence following chemotherapy.
Wnt pathway
Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival
The Wnt pathways control key biological processes that potentially impact on tumour progression and patient survival. We are evaluating DNA methylation at promoter CpG islands (CGIs) of Wnt pathway genes in ovarian tumours at presentation and identify biomarkers of patient progression-free survival.
Chemotherapy and Overexpress
The histone methyltransferase EZH2 is a key component of the Polycomb Repressive Complex 2 (PRC2) required for maintenance of a stem cell state and overexpression has been implicated in drug resistance and shorter survival of ovarian cancer patients.
Biomarkers of Progression-Free Survival
The association of methylation and progression free survival was examined by Cox proportional hazards model.